Supplementary Material for: A case: Thrombocytopenia in an EGFR 19 exon-deficient bilateral diffuse LUAD with ARDS treated with ECMO and Osimertinib

Introduction: EGFR-sensitive mutations bilateral-diffuse lung adenocarcinoma (LUAD) complicated with acute respiratory distress syndrome (ARDS)is relatively rare. Whether EGFR-TKI can be simultaneously received when treating with extracorporeal membrane oxygenation (ECMO) and anti-infective therapy in these patients, and what adverse events should be noted?
Case Presentation: We report a case of EGFR 19 exon-deficient bilateral diffuse LUAD complicated with ARDS. When treated with ECMO and anti-infective therapy, the patient received oral Osimertinib anti-tumor therapy simultaneously. The tumor receded, but eventually irreversible thrombocytopenia developed.
Conclusion: For patients with severe lung cancer, anti-tumor efficacy and adverse events should be closely observed during anti-tumor therapy.

引言：EGFR敏感突变型双侧弥漫性肺腺癌（LUAD）合并急性呼吸窘迫综合征（ARDS）相对罕见。此类患者在接受体外膜肺氧合（ECMO）及抗感染治疗期间，能否同步接受表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗，且需注意哪些不良事件？
病例报告：我们报告1例EGFR 19外显子缺失型双侧弥漫性LUAD合并ARDS的病例。患者在接受ECMO及抗感染治疗期间，同步口服奥希替尼（Osimertinib）进行抗肿瘤治疗，肿瘤出现退缩，但最终发生不可逆性血小板减少症。
结论：对于重症肺癌患者，在抗肿瘤治疗期间应密切观察其抗肿瘤疗效及不良事件。